Clinical Science

"The progressive nature of ADPKD means that kidney function gets worse over time, eventually leading to end-stage renal disease. This progression happens more rapidly for some patients than others.” said Michal Mrug, M.D., Associate Professor at the University of Alabama at Birmingham and investigator on the REPRISE trial. “Today’s approval is great news for adults at risk of rapidly progressing ADPKD because by slowing the decline in kidney function, this therapy may give them more time before kidney transplant or dialysis.”

The culmination of collaborative work between the Centre of Evidence-Based Medicine and the University of Oxford, the website, Catalogue of Biases, is a complete database of possible biases that inadvertently make their way into scientific research.

ASN and the U.S. Department of Health and Human Services (HHS) have sent a clear signal in their desire to have new therapies in the kidney space through the signing of a Memorandum of Understanding establishing the Kidney Innovation Accelerator (KidneyX), a collaborative environment in which a community of researchers, innovators, and investors can participate.

The BMJ compiled an archive on their website entitled “Statistics notes”. The archive includes numerous notes and articles that examine different research methods and statistical reporting, which are useful resources for anyone conducting their own research.